VolitionRx Spotlights Nu.Q® Vet Cancer Test at VMX 2026
Event summary
- VolitionRx sponsors a symposium at VMX 2026 in Orlando, Florida, on January 19, 2026.
- Dr. Sue Ettinger presents on integrating Nu.Q® Vet Cancer Test into veterinary practice.
- VolitionRx aims to promote early cancer detection in pets through its Nu.Q® Canine Cancer Test.
- The event attracts approximately 20,000 veterinary professionals.
The big picture
VolitionRx's sponsorship of VMX 2026 underscores its push into veterinary diagnostics, leveraging epigenetics for early cancer detection. The move aligns with broader trends in precision medicine, where early intervention improves outcomes. With approximately 20,000 attendees, VMX provides a critical platform to showcase Nu.Q® Vet Cancer Test and drive adoption among veterinary professionals.
What we're watching
- Market Adoption
- How quickly veterinarians integrate Nu.Q® Vet Cancer Test into routine checkups.
- Competitive Positioning
- Whether VolitionRx can sustain leadership in veterinary epigenetics diagnostics.
- Regulatory Approvals
- The pace at which VolitionRx secures necessary regulatory clearances for its tests.
Related topics